The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4a cohort.
 
Akihiro Homma
Consulting or Advisory Role - Olympus Medical Systems; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Eisai; Makichie; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nobelpharma; Ono Pharmaceutical; Sanofi
Research Funding - Eisai (Inst); Kyorin (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Kazuto Matsuura
No Relationships to Disclose
 
Rikiya Onimaru
No Relationships to Disclose
 
Daisuke Yoshida
No Relationships to Disclose
 
Hirotaka Shinomiya
No Relationships to Disclose
 
Akira Ohkoshi
No Relationships to Disclose
 
Ryuichi Hayashi
Consulting or Advisory Role - Rakuten Medical Japan
 
Yuki Saito
No Relationships to Disclose
 
Hiroyuki Tachibana
No Relationships to Disclose
 
Kiyoto Shiga
No Relationships to Disclose
 
Tsutomu Ueda
Honoraria - Bayer; Mitsubishi Tanabe Pharma; MSD; ONO PHARMACEUTICAL; Taiho Pharmaceutical
Research Funding - ONO PHARMACEUTICAL
 
Yukinori Asada
No Relationships to Disclose
 
Hirokazu Uemura
No Relationships to Disclose
 
Akira Seto
No Relationships to Disclose
 
Takeshi Beppu
No Relationships to Disclose
 
Kazuki Ishikawa
No Relationships to Disclose
 
Masashi Mikami
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Chugai Pharma; IQvia; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Haruhiko Fukuda
Honoraria - Chugai Pharma
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - ASCENT Development Services; Ono Pharmaceutical; Shift Zero
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - Adlai Nortye (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical; Roche (Inst)